Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Focal vibration in neurorehabilitation.
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Alemtuzumab benefits hard-to-treat MS patients
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients

Pages